Guochuan Emil Tsai
Research Subjects
Guochuan Emil Tsai has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Lu-Ping Lu
Department of Research and Development, SyneuRx International (Taiwan) Corp.; Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University
3 shared publicationsTeh-Ying Chou
Institute of Biochemistry & Molecular Biology, National Yang Ming Chiao Tung University, Taipei, 112304, Taiwan
3 shared publicationsYi-Wen Mao
Department of Research and Development, SyneuRx International (Taiwan) Corp
3 shared publicationsHan-Yi Hsieh
Department of Research & Development, SyneuRx International (Taiwan) Corp., New Taipei, 221416,Taiwan
2 shared publicationsJhe-Wei Hu
Department of Research & Development, SyneuRx International (Taiwan) Corp., New Taipei, 221416,Taiwan
2 shared publicationsJui-Fu Hsiao
Department of Research and Development, SyneuRx International (Taiwan) Corp., New Taipei City, Taiwan
2 shared publications
Latest Publications
- 12 June 2024
- Published by Taylor & Francis in Future Virology
- Vol. 19 (8-9) , 299-314
Ultrapure and potent tannic acid as a pluripotent protease and influenza HA inhibitor against influenza virus infection
- 12 June 2024
- Published by Taylor & Francis in Future Virology
- Vol. 19 (8-9) , 299-314
Ultrapure and potent tannic acid as a pluripotent protease and influenza HA inhibitor against influenza virus infection
- Open Access
- 12 April 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 853
The Development of a Regulator of Human Serine Racemase for N-Methyl-D-aspartate Function
It is crucial to regulate N-methyl-D-aspartate (NMDA) function bivalently depending on the central nervous system (CNS) conditions. CNS disorders with NMDA hyperfunction are involved in the pathogenesis of neurotoxic and/or neurodegenerative disorders with elevated D-serine, one of the NMDA receptor co-agonists. On the contrary, NMDA-enhancing agents have been demonstrated to improve psychotic symptoms and cognition in CNS disorders with NMDA hypofunction. Serine racemase (SR), the enzyme regulating both D- and L-serine levels through both racemization (catalysis from L-serine to D-serine) and β-elimination (degradation of both D- and L-serine), emerges as a promising target for bidirectional regulation of NMDA function. In this study, we explored using dimethyl malonate (DMM), a pro-drug of the SR inhibitor malonate, to modulate NMDA activity in C57BL/6J male mice via intravenous administration. Unexpectedly, 400 mg/kg DMM significantly elevated, rather than decreased (as a racemization inhibitor), D-serine levels in the cerebral cortex and plasma. This outcome prompted us to investigate the regulatory effects of dodecagalloyl-α-D-xylose (α12G), a synthesized tannic acid analog, on SR activity. Our findings showed that α12G enhanced the racemization activity of human SR by about 8-fold. The simulated and fluorescent assay of binding affinity suggested a noncooperative binding close to the catalytic residues, Lys56 and Ser84. Moreover, α12G treatment can improve behaviors associated with major CNS disorders with NMDA hypofunction including hyperactivity, prepulse inhibition deficit, and memory impairment in animal models of positive symptoms and cognitive impairment of psychosis. In sum, our findings suggested α12G is a potential therapeutic for treating CNS disorders with NMDA hypofunction.
- 12 April 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 853
Open AccessThe Development of a Regulator of Human Serine Racemase for N-Methyl-D-aspartate Function
It is crucial to regulate N-methyl-D-aspartate (NMDA) function bivalently depending on the central nervous system (CNS) conditions. CNS disorders with NMDA hyperfunction are involved in the pathogenesis of neurotoxic and/or neurodegenerative disorders with elevated D-serine, one of the NMDA receptor co-agonists. On the contrary, NMDA-enhancing agents have been demonstrated to improve psychotic symptoms and cognition in CNS disorders with NMDA hypofunction. Serine racemase (SR), the enzyme regulating both D- and L-serine levels through both racemization (catalysis from L-serine to D-serine) and β-elimination (degradation of both D- and L-serine), emerges as a promising target for bidirectional regulation of NMDA function. In this study, we explored using dimethyl malonate (DMM), a pro-drug of the SR inhibitor malonate, to modulate NMDA activity in C57BL/6J male mice via intravenous administration. Unexpectedly, 400 mg/kg DMM significantly elevated, rather than decreased (as a racemization inhibitor), D-serine levels in the cerebral cortex and plasma. This outcome prompted us to investigate the regulatory effects of dodecagalloyl-α-D-xylose (α12G), a synthesized tannic acid analog, on SR activity. Our findings showed that α12G enhanced the racemization activity of human SR by about 8-fold. The simulated and fluorescent assay of binding affinity suggested a noncooperative binding close to the catalytic residues, Lys56 and Ser84. Moreover, α12G treatment can improve behaviors associated with major CNS disorders with NMDA hypofunction including hyperactivity, prepulse inhibition deficit, and memory impairment in animal models of positive symptoms and cognitive impairment of psychosis. In sum, our findings suggested α12G is a potential therapeutic for treating CNS disorders with NMDA hypofunction.
- Open Access
- 26 December 2023
- Published by Academic Publishing Pte. Ltd. in Journal of Toxicological Studies
- Vol. 1 (1) , 245
Toxicological evaluation of Ultrapure and Potent Tannic Acid (UPPTA) by inhalation exposure
The therapeutic options for coronal virus infections are limited. As SARS-CoV-2 directly targets the lungs and causes lung damage, treatment of COVID-19 with inhalants may offer more advantages over oral administration. Inhaled drug delivery provides a higher drug concentration in the target organ, where SARS-CoV-2 proliferates. In this study, we evaluated the potential systemic toxicity, relevant target organ toxicity, and toxicokinetics of Airnecflu®, Ultrapure, and Potent Tannic Acid (UPPTA) by metered-dose inhaler (MDI) inhalation to rodent and canine species once a day for 2 consecutive weeks. We further investigated the reversibility of the toxicity following a 3-week recovery period. No mortality related to the test article was observed in all the dose groups. Neither abnormalities related to the test article nor toxicologically significant changes were observed in both rodent and canine studies. In pathological examination, alveolar macrophage aggregation, perivascular/interstitial/alveolar inflammatory cell infiltration, and alveolar/bronchial epithelium hyperplasia were noted in the lung with bronchial involvement. However, after a 3-week recovery period, a substantial recovery was observed. There is limited systemic exposure to the inhalation administration. Therefore, inhalation of Airnecflu® UPPTA is safe to administer for respiratory disorders like COVID-19.
- 26 December 2023
- Published by Academic Publishing Pte. Ltd. in Journal of Toxicological Studies
- Vol. 1 (1) , 245
Open AccessToxicological evaluation of Ultrapure and Potent Tannic Acid (UPPTA) by inhalation exposure
The therapeutic options for coronal virus infections are limited. As SARS-CoV-2 directly targets the lungs and causes lung damage, treatment of COVID-19 with inhalants may offer more advantages over oral administration. Inhaled drug delivery provides a higher drug concentration in the target organ, where SARS-CoV-2 proliferates. In this study, we evaluated the potential systemic toxicity, relevant target organ toxicity, and toxicokinetics of Airnecflu®, Ultrapure, and Potent Tannic Acid (UPPTA) by metered-dose inhaler (MDI) inhalation to rodent and canine species once a day for 2 consecutive weeks. We further investigated the reversibility of the toxicity following a 3-week recovery period. No mortality related to the test article was observed in all the dose groups. Neither abnormalities related to the test article nor toxicologically significant changes were observed in both rodent and canine studies. In pathological examination, alveolar macrophage aggregation, perivascular/interstitial/alveolar inflammatory cell infiltration, and alveolar/bronchial epithelium hyperplasia were noted in the lung with bronchial involvement. However, after a 3-week recovery period, a substantial recovery was observed. There is limited systemic exposure to the inhalation administration. Therefore, inhalation of Airnecflu® UPPTA is safe to administer for respiratory disorders like COVID-19.
- Open Access
- 4 September 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 42, 100899
Suicide attempts in French Polynesia during the era of COVID-19: a prospective analysis over three years
- 4 September 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 42, 100899
Open AccessSuicide attempts in French Polynesia during the era of COVID-19: a prospective analysis over three years
- Open Access
- 19 December 2022
- Published by Georg Thieme Verlag KG in European Journal of Dentistry
- Vol. 17 (03) , 863-870
Acidic Microenvironment–Sensitive Core-Shell Microcubes: The Self-assembled and the Therapeutic Effects for Caries Prevention
Objectives The aim of this study was to develop a new material with integrated interface design that could achieve the purpose of environmental-sensing controlled release against cariogenic bacteria. Furthermore, this material can rebalance oral flora and serve as a preventive and reparative measure of dental caries. Materials and Methods NaF@PAA@HA@polyelectrolytes@HA@PAA particles were synthesized using the method of two-solution phases precipitation followed by biocompatible polymers coating layer by layer. The structure of the particles was confirmed by transmission electron microscope. The fluoride release profile was measured by fluoride ion electrode. Antimicrobial activity against the cariogenic microorganisms was analyzed by scanning electron microscopy and energy dispersive spectrum. The efficacy experiments were conducted on tooth enamel slides to evaluated fluoride absorption and antibacterial activity of the prototype toothpaste containing microcube particles Results The structure of NaF@PAA@HA@polyelectrolytes@HA@PAA particles showed a core surrounded by tooth-adhesion polymer layers in thin fin or filament structure. The loaded concentration of fluoride in the particles' core was 148,996 ± 28,484 ppm. NaF@PAA@HA@polyelectrolytes@HA@PAA particles showed selective inhibition of cariogenic microorganisms over probiotic strains and stronger fluoride adhesion on tooth enamel. A burst release (over 80%) of fluoride from the particle-containing toothpaste was observed under cariogenic acidic environment (pH < 5), while it remained extremely low under neutral environment. Compared with the best results of commercial toothpastes, our prototype toothpaste increased enamel fluoride uptake by 8-fold in normal enamel slides and by 11-fold in the slides with induced white spot lesions after either 1- or 7-day treatment. The prototype toothpaste also showed better inhibition of cariogenic microorganisms than the commercial brands. The coverage area of cariogenic bacteria under our toothpaste treatment was 73% on normal enamel slides compared with the commercial brands, while it was 69% in the induced white spot lesions. Conclusions In our study, an intelligent toothpaste was developed that selectively inhibits cariogenic bacteria by microenvironment proton-triggered fluoride release. Such novel design would accomplish a favorable flora balance for optimal long-term oral health.
- 19 December 2022
- Published by Georg Thieme Verlag KG in European Journal of Dentistry
- Vol. 17 (03) , 863-870
Open AccessAcidic Microenvironment–Sensitive Core-Shell Microcubes: The Self-assembled and the Therapeutic Effects for Caries Prevention
Objectives The aim of this study was to develop a new material with integrated interface design that could achieve the purpose of environmental-sensing controlled release against cariogenic bacteria. Furthermore, this material can rebalance oral flora and serve as a preventive and reparative measure of dental caries. Materials and Methods NaF@PAA@HA@polyelectrolytes@HA@PAA particles were synthesized using the method of two-solution phases precipitation followed by biocompatible polymers coating layer by layer. The structure of the particles was confirmed by transmission electron microscope. The fluoride release profile was measured by fluoride ion electrode. Antimicrobial activity against the cariogenic microorganisms was analyzed by scanning electron microscopy and energy dispersive spectrum. The efficacy experiments were conducted on tooth enamel slides to evaluated fluoride absorption and antibacterial activity of the prototype toothpaste containing microcube particles Results The structure of NaF@PAA@HA@polyelectrolytes@HA@PAA particles showed a core surrounded by tooth-adhesion polymer layers in thin fin or filament structure. The loaded concentration of fluoride in the particles' core was 148,996 ± 28,484 ppm. NaF@PAA@HA@polyelectrolytes@HA@PAA particles showed selective inhibition of cariogenic microorganisms over probiotic strains and stronger fluoride adhesion on tooth enamel. A burst release (over 80%) of fluoride from the particle-containing toothpaste was observed under cariogenic acidic environment (pH < 5), while it remained extremely low under neutral environment. Compared with the best results of commercial toothpastes, our prototype toothpaste increased enamel fluoride uptake by 8-fold in normal enamel slides and by 11-fold in the slides with induced white spot lesions after either 1- or 7-day treatment. The prototype toothpaste also showed better inhibition of cariogenic microorganisms than the commercial brands. The coverage area of cariogenic bacteria under our toothpaste treatment was 73% on normal enamel slides compared with the commercial brands, while it was 69% in the induced white spot lesions. Conclusions In our study, an intelligent toothpaste was developed that selectively inhibits cariogenic bacteria by microenvironment proton-triggered fluoride release. Such novel design would accomplish a favorable flora balance for optimal long-term oral health.
- Open Access
- 15 December 2022
- Published by Elsevier in Phytomedicine Plus
- Vol. 3 (1)
Ultrapure and potent tannic acid (UPPTA) is a novel inhibitor of D-amino acid oxidase to improve the N-methyl-D-aspartate function of CNS disorders
- 15 December 2022
- Published by Elsevier in Phytomedicine Plus
- Vol. 3 (1)
Open AccessUltrapure and potent tannic acid (UPPTA) is a novel inhibitor of D-amino acid oxidase to improve the N-methyl-D-aspartate function of CNS disorders
- Open Access
- 13 May 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (6) , 400-412
Development of Ultrapure and Potent Tannic Acids as a Pan-coronal Antiviral Therapeutic
- 13 May 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (6) , 400-412
Open AccessDevelopment of Ultrapure and Potent Tannic Acids as a Pan-coronal Antiviral Therapeutic
- 10 January 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (32) , 5118-5126
NMDA Pathology and Treatment of Schizophrenia
Schizophrenia, a multifactorial mental disorder with polygenic inheritance as well as environmental influences, encompasses a characteristic group of symptoms. Negative and cognitive symptoms which respond poorly to currently available antipsychotics remain a great clinical challenge. Aggressive studies are ongoing to explore the etiological mechanisms of this disease. Among them, one of the primary causal factors is dysfunction of the N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews the clinical manifestations of the disease, limitations of current antipsychotics and reconceptualization of the nature of disease and treatment modalities based on the evidence provided by drug models, genetic studies, and clinical trials. The NMDA receptor (NMDAR) model plays a critical role in the revolution of pharmaceutical industry as a new set of drug targets is proposed. Investigations on the modulation of glutamatergic system, particularly the intrinsic NMDA glycine modulatory site, exhibit encouraging results. A group of “NMDA-enhancing agents” either acts directly or indirectly on the glycine modulatory site, showing therapeutic efficacy in preclinical and early clinical trials. A new generation of therapeutic agents targeting the NMDAR shows promise as the next wave of drug development for schizophrenia.
- 10 January 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 20 (32) , 5118-5126
NMDA Pathology and Treatment of Schizophrenia
Schizophrenia, a multifactorial mental disorder with polygenic inheritance as well as environmental influences, encompasses a characteristic group of symptoms. Negative and cognitive symptoms which respond poorly to currently available antipsychotics remain a great clinical challenge. Aggressive studies are ongoing to explore the etiological mechanisms of this disease. Among them, one of the primary causal factors is dysfunction of the N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews the clinical manifestations of the disease, limitations of current antipsychotics and reconceptualization of the nature of disease and treatment modalities based on the evidence provided by drug models, genetic studies, and clinical trials. The NMDA receptor (NMDAR) model plays a critical role in the revolution of pharmaceutical industry as a new set of drug targets is proposed. Investigations on the modulation of glutamatergic system, particularly the intrinsic NMDA glycine modulatory site, exhibit encouraging results. A group of “NMDA-enhancing agents” either acts directly or indirectly on the glycine modulatory site, showing therapeutic efficacy in preclinical and early clinical trials. A new generation of therapeutic agents targeting the NMDAR shows promise as the next wave of drug development for schizophrenia.